Dr Sandeep Arora
Professor and Director (CCP)


Expert Areas : Phytochemistry, Drug Development, Preclinical and clinical evaluation, Pharma regulations

Dr Sandeep Arora, PhD Pharma Sciences, PG Dip HRM, PG Dip Pharma Project management carries a professional experience spanning 27years, with initial 4 years as Executive in Pharma Operations and QA in multinational Pharma Companies including Glaxo I Ltd, Nasik, India, Blue cross Labs Ltd, and 23 years in Pharma Academics/training and research. His area of Pharmaceutical research has been centered around Phytopharmaceuticals, Drug discovery, development, Pharmaceutical regulations, Industrial Pharmacy, and Pharmaceutical management. He has 90 publications to his credit, with an h-index of 9, authored three books

“Pharmaceuticals – Issues for Industrial Management”

“Leadership…over the years, Society and nations…between the ears!!”

“Metastatic Diseases: Novel Approaches to Diagnostic and Therapeutic Management”

He has 14 patents filed around the above cited research areas, has registered 4 Trademarks and a Company ARROWSANDS Group and has been the honorary editor of “Advance Drug Review”, ADR—a quarterly drug Pharmacology review index—since 2005, is Editorial Board member of International Journal of Inflammation, UK, Editor, Journal of Pharma Technology, Research and management, JPTRM, CU. He has been appointed as an Auditor (Pharma) for AQA, New Zealand. He has guided 7 Ph.D. thesis (currently guiding 10 PhD students),  25 M. Pharm. Students. He has been involved in 2 product launches at international level. He has convened 11 National/international conferences as Chairman, was Co Convener, 69th Indian Pharma Congress-IPC, 2017, and is a regular expert speaker at OMICS, US and ASSOCHAM India conferences, Pfizer-IPA-CPD speaker, and invited offshore speaker at Univ of Florida. He is member APTI, Indian Pharma Association (IPA), and Pharmacy Council of India (PCI) and Life member Inflammation Society, and consultant and advisor to Pharma industry on regulatory compliance and herbal product standardisation. He has been providing industrial consultancy to various Pharma Companies on product development, standardization and regulatory filings. He is on Advisory Board Panel to Natural Solutions, Mumbai, Amulya Herbs, Panchkula, Pharexcel Consulting, Bangalore.

  • Research
  • Teaching
  • Patents
  • Education
  1. Arora S. and Rawat A.K.S. (2007) “Lysosomal enzyme inhibiting activity of Flavone fraction from Tylophoraindica leaves in arthritic rats.”  PhCogMag, Vol. 3, Issue 12, pp 226-232.
  2. Arora S. and Singh H.K. (2007) “Lysosomal enzyme inhibiting activity of alkaloidal fraction from Tylophoraindica leaves in arthritic rats”. Natural Product Sciences, Vol. 13, No. 4, pp 289-294.
  3. Sandeep Arora,Mahashweta Roy, ShubhiniSaraf(2009) “Pharmacognostic and phytochemical investigation of Cordiadichotoma seeds.” PhCog J., Vol. 1, Issue 1. pp 67-72.
  4. Sandeep Arora,Pradeep Kumar, I. Singh and Rakesh K. Sindhu(2009)Development and Characterization of Chitosan and Polymethylmethacrylate Interpenetrating Polymer Network Ophthalmic Inserts. International Journal of Pharm Tech Research,Vol.1, No.4, pp 1241-1246.
  5. Sandeep Arora, Anurag Mishra, Rajiv Gupta, Manvi, Rajesh Kumar Punia and Ashish Kumar Sharma. Effect of Feroniaelephantum(Corr) Fruit Pulp Extract on Indomethacin-induced Gastric Ulcer in Albino Rats.”  Tropical Journal of Pharmaceutical Research, December 2009; 8 (6): 509-514.
  6. Sandeep Arora, Rehni AK, Singh TG, “Possible Involvement of Ubiquitin Proteasome System and Other Proteases in Acute and Delayed Aspects of Ischemic Preconditioning of Brain in Mice.”Biological& Pharmaceutical Bulletin,2010, 33 (12), 1953-57.
  7. Sandeep Arora, Gurpreetsingh, Karan Malik, Inderbirsingh.“Formulation and Evaluation of Controlled Release Mucoadhesive Matrix Tablets: Assessment of Myrrh Oleogum resin as a Natural Pharmaceutical excipient”, International J Pharm Sci and Drug Res, 2011, 3 (2), 84-88.
  8. Sandeep Arora,Ashish K Rehni, Thakur GurjeetSingh,TarunKakkar. “Involvement of src kinase activation in ischemic preconditioning induced protection of mouse brain”, Life sciences (2011), 88 (19-20), 825-29. doi;10.1016/j.lfs.2011.02.024
  9. Rakesh K Sindhu and S Arora. Herbs for the treatment of Arthritis and inflammation: A review.  PlantaActiva, 2012, 3, 152-157.
  10. Rakesh K Sindhu and S Arora. Phytochemical and Pharmacognostical studies on MurrayakoenigL .spreng roots. Drug Invention Today.  2012, 4(1), 325-336. (Impact Factor 0.64).
  11. Rakesh K Sindhu and S Arora. Evaluation of phenolic contents and antioxidant potential of Murrayakoenigii(L) spreng roots. Journal of Applied Pharmaceutical Science, 2012, 2(11), 220-222.
  12. Rakesh K Sindhu and S Arora.  Therapeutic effect of Ficuslacor aerial roots of various fractions on Adjuvant-Induced Arthritic rats.  ISRN Pharmacology, 2013, 1-8.
  13. Rakesh K Sindhu and S Arora. Phytochemical and Pharmacognostical investigations on Ficuslacor aerial roots. International Journal of Phytomedicine, 2013, 5(3), 267-277. (Impact Factor 1.09).
  14. Rakesh K Sindhu and S Arora. Free radical scavenging and antioxidant activity of FicuslacorBuch. Hum.AsianJournal of pharmaceutical and clinical research.2013, 6(5). 184-186. (Impact Factor 0.70).
  15. Rakesh K Sindhu and S Arora. Anti-inflammatory potential of various extract fractions of Ficuslacor aerial roots and Murrayakoenigii roots. Archives of Biological Sciences. 2014, 66 (3), 1261-1270. (Impact Factor 0.607).
  16. Sukhbir Singh Sandeep Arora,Neelam Singh and DharnaAllawadi, 2014: Formulation, Optimization and Evaluation of Sustained Release Microsphers using Taguchi DesignV ol.-2, 1, 253
  17. Singh TG, Rehni AK, Arora SK. Pharmacological modulation of farnesyltransferase subtype I attenuates mecamylamine-precipitated nicotine withdrawal syndrome in mice. 2013 Dec;24(8):668-77. Impact factor: 2.26
  18. Singh TG, Rehni AK, Arora S. Ro 32-0432 attenuates mecamylamine-precipitated nicotine withdrawal syndrome in mice.NaunynSchmiedebergs Arch Pharmacol. 2013 Mar; 386(3): 197-204. Impact factor: 2.36
  19. Singh TG, Rehni AK, Arora S. SU-6656, a selective Src kinase inhibitor, attenuates mecamylamine-precipitated nicotine withdrawal syndrome in mice. Nicotine Tob Res. 2012 Apr; 14(4): 407-14. Impact factor: 3.125

Teaching : Phytochemistry, Drug Development, Phytopharmaceutical formulations, preclinical and clinical evaluation, industrial processing, pharma regulations, industrial management.

Field of Specialization – Drug Development, industrial technology, regulations, and phytopharmaceuticals.

  • Dermal Patch of Curcumin, for Therapeutic use
  • Crossed Linked Carboxymethylated Xanthan as Super Disintegran.
  • Resveratrol derivatives as novel therapeutic agents
  • Novel compounds with anti-inflammatory activity (Ferulic acid derivatives): Dr Sandeep Arora
  • 5. Improved formulation of Glimepride with enhanced solubility
  • Improved Oral Formulations of RosuvastatinNanocrystals with enhanced bioavailability and method thereof
  • Novel Boswellic Acid derivatives with therapeutic activity
  • Novel herbal sunscreen lotion.
  • BSc
  • B Pharm
  • M Pharm
  • PhD